Clinical Trials Directory

Trials / Completed

CompletedNCT01227148

Influence of Tightly Glucose Control on Hyperglycemic Toxicity and Protein Catabolism in Critically Ill Patients

Influence of Tightly Glucose Control on Hyperglycemic Toxicity and Protein

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
112 (actual)
Sponsor
Kaohsiung Veterans General Hospital. · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To compare the differences of urinary nitrogen excretion, nitrogen balance and clinical outcomes between tightly insulin therapy and conventional insulin therapy in the ICU.

Detailed description

Critical illness is associated with increased circulating concentrations of proinflammatory cytokines, such as tumor necrosis factor (TNF-α), interleukin (IL)-1, and IL-6 which may be important mediators of insulin resistance and results in hyperglycemia. Altered glucose metabolism was caused by release of counter regulatory hormones such as glucagons; epinephrine and cortisol oppose the normal action of insulin, leading to an increase in skeletal muscle proteolysis. It did not know whether tightly glucose control had beneficial effect in urinary nitrogen excretion and nitrogen balance.

Conditions

Interventions

TypeNameDescription
OTHERTightly glucose controlA continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
OTHERConventional glucose controla continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.

Timeline

Start date
2006-04-01
Primary completion
2006-12-01
Completion
2006-12-01
First posted
2010-10-25
Last updated
2010-10-25

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT01227148. Inclusion in this directory is not an endorsement.